|
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome Clinical research trials and A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome. A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome clinical trial. Human subjects frequently get the finest healthcare available for their A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome  A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
For Condition: Cachexia,HIV Infections,HIV Wasting Syndrome
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Roxane Laboratories,Bristol-Myers Squibb
Synopsis: To obtain data on the safety of administering megestrol acetate and dronabinol as single agents or in combination to patients with human immunodeficiency virus (HIV)-wasting syndrome. To obtain preliminary data on the efficacy of single agent and combination therapy with megestrol acetate and dronabinol with regard to weight gain, appetite increase and quality of life in this patient population. To obtain steady-state pharmacokinetics data when megestrol acetate and dronabinol are administered as single agents and in combination. HIV-wasting syndrome, which is characterized by severely debilitating anorexia and weight loss, is of particular concern because it can exacerbate the primary illness and is associated with a poor prognosis. Attempts at maintaining body mass through the use of megestrol acetate and dronabinol, two anti-cachectic drugs, may prolong survival.
Details: HIV-wasting syndrome, which is characterized by severely debilitating anorexia and weight loss, is of particular concern because it can exacerbate the primary illness and is associated with a poor prognosis. Attempts at maintaining body mass through the use of megestrol acetate and dronabinol, two anti-cachectic drugs, may prolong survival. Fifty-six patients are randomized to one of four treatment arms, as follows: high-dose megestrol acetate alone; dronabinol alone; high-dose megestrol acetate combined with dronabinol; or low-dose megestrol acetate combined with dronabinol. Treatment continues for 12 weeks. Patients are evaluated for toxicity, preliminary evidence of response (e.g., weight gain), and steady-state pharmacokinetics of drug therapies.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC). If initiating new antiretroviral therapy, patient must have been on a stable dose for at least 4 weeks prior to study entry. - Maintenance or suppressive therapy with any of the following, provided patient has been on a stable dose for at least 1 week prior to study entry: - Ganciclovir or foscarnet for CMV retinitis. - Fluconazole, amphotericin B, or flucytosine for cryptococcosis. - Amphotericin B for disseminated histoplasmosis. - Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis. - Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex. - Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis. - Any of the following provided patient is on a stable dose for at least 1 week prior to study entry: - Trimethoprim-sulfamethoxazole, aerosolized pentamidine, or dapsone for Pneumocystis carinii prophylaxis. - Clotrimazole troches, nystatin suspension, ketoconazole, or fluconazole for oral candidiasis. - Oral acyclovir for mucocutaneous herpes simplex. - Narcotic analgesics, tranquilizers, sedative-hypnotics, or anticholinergic agents provided patient is on a stable dose for at least 1 week prior to study entry. Patients must have: - HIV infection. - HIV-wasting syndrome and anorexia. - Life expectancy of at least 4 months. - Ability to tolerate oral therapy, feed themselves, and have access to as much food as they desire with no dietary restrictions. Prior Medication: Allowed: - Prior zidovudine (AZT), didanosine (ddI), and dideoxycytidine (ddC). - Prior maintenance or suppressive therapy for certain opportunistic infections, as follows: - Ganciclovir or foscarnet for CMV retinitis. - Fluconazole, amphotericin B, or flucytosine for cryptococcosis. - Amphotericin B for disseminated histoplasmosis. - Pyrimethamine, sulfadiazine, dapsone, or clindamycin for toxoplasmosis. - Amikacin, clarithromycin, clofazimine, ethambutol, ciprofloxacin, or rifampin for disseminated Mycobacterium avium complex. - Isoniazid, rifampin, ethambutol, or pyrazinamide for M. tuberculosis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Major, acute opportunistic infections. - Active neoplasms other than Kaposi's sarcoma or localized skin carcinoma. - Diabetes, congestive heart failure, clinical ascites, or uncontrolled hypertension. - Persistent grade 3/4 diarrhea. - Impaired oral intake, such as occurs with Candida esophagitis or severe mouth ulcers. - Clinically significant cardiac arrhythmias. - Requirement for anticonvulsants for seizure disorder. Concurrent Medication: Excluded: - Marijuana use. - Anabolic steroids. - Anticonvulsants for seizure disorders. - Alcohol or barbiturates. Patients with the following prior conditions are excluded: - Diagnosis of a major, acute opportunistic infection within 2 months prior to study entry. - Hospitalization within 2 weeks prior to study entry. - History of hypersensitivity reactions to megestrol acetate, dronabinol, or sesame oil (a component of the dronabinol capsules). - History of thromboembolic events. - History of psychiatric disorder other than depression. Prior Medication: Excluded: - Prior dronabinol. - Megestrol acetate within 2 months prior to study entry. - Marijuana within 1 month prior to study entry. - Anabolic steroids within 3 months prior to study entry. Current drug or alcohol abuse (patients with a history of occasional marijuana use are eligible provided they have abstained from its use for 1 month prior to study entry and agree to refrain from marijuana use for the study period).
Total Enrollment: 56
Location and Contact Information:
Overall Study Official:
GalettoG, Study Chair,
Portland Veterans Adm Med Ctr / Rsch & Education Grp
Portland, Oregon, 972109951
United States
Univ of Maryland at Baltimore / Veterans Adm
Baltimore, Maryland, 21201
United States
Tulane Univ Med School
New Orleans, Louisiana, 701122699
United States
Univ of Rhode Island / College of Pharmacy
Providence, Rhode Island, 02908
United States
Washington Univ
St. Louis, Missouri, 63110
United States
Univ of Kansas School of Medicine
Wichita, Kansas, 67214
United States
Denver Public Health Dept
Denver, Colorado, 802044507
United States
SUNY / Health Sciences Ctr at Brooklyn
Brooklyn, New York, 11203
United States
Univ of Illinois
Chicago, Illinois, 60612
United States
Additional Information:
Study ID Numbers: DATRI 004;
Study Start Date:
Record last reviewed: January 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000737
Other Cachexia Studies:
1. Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
2. Creatine in Treating Patients With Cancer-Associated Weight Loss
3. A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
4. Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
5. Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
Related Studies:
Other Cachexia Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
|
|
|
|
|
|
|
|
